1. Pink Sheet
  2. >>Geography
  3. >>Europe

Actelion And Bayer Hope Novel Drugs Can Take Over The Pulmonary Hypertension Market

 
• By Sten Stovall

Impressive Phase III trial data on Actelion’s macitentan and Bayer’s riociguat generated big noises at the annual meeting of the American College of Chest Physicians in Atlanta and should support regulatory filings for the two therapies.

With competition in the pulmonary arterial hypertension market tight, Swiss biotech Actelion Pharmaceuticals Ltd. and Germany’s Bayer AGare hoping that competitive advantages with their experimental lung drugs could be enough to break their way in.

Actelion – Europe’s biggest biotech by market capitalization – already holds the majority share with its endothelin receptor antagonist Tracleer (bosentan), but that powerhouse will be going off patent in 2015 and faces growing competition from Gilead Sciences Inc

More from Europe

More from Geography

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.